Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

(2021) Juan P. Frias et al.   DIABETES CARE

Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis

(2020) Humaira Hussein et al.   DIABETES OBESITY & METABOLISM

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

(2019) Bernard Zinman et al.   Lancet Diabetes & Endocrinology

Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example

(2019) Vanita R. Aroda et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

(2019) M.S. Capehorn et al.   DIABETES & METABOLISM

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

(2019) Ildiko Lingvay et al.   Lancet Diabetes & Endocrinology

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

(2019) Vanita R. Aroda et al.   DIABETES OBESITY & METABOLISM

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

(2019) Kelsey H Sheahan et al.   POSTGRADUATE MEDICAL JOURNAL

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

(2018) Ildiko Lingvay et al.   DIABETES CARE

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

(2018) Helena W Rodbard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

(2018) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis

(2018) Dan Qian et al.   PLoS One

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

GLP-1 receptor agonists: a review of head-to-head clinical studies

(2014) Jennifer M. Trujillo et al.   Therapeutic Advances in Endocrinology and Metabolism

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE